<DOC>
	<DOC>NCT00388518</DOC>
	<brief_summary>This 6 arm study will assess the efficacy, safety, tolerability and pharmacokinetics of aleglitazar therapy in patients with Type 2 diabetes. Patients will be randomised to one of 6 treatment arms, to receive one of 4 doses of aleglitazar, Actos as an open-label active comparator, or placebo. Aleglitazar will be administered starting from a dose of 0.05mg po daily, and Actos will be administered at a dose of 45mg once daily. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Aleglitazar in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>adult patients, 1875 years of age; type 2 diabetes, diagnosed &gt;=1 month of screening; either drugnaive, or pretreated with a maximum of 2 oral antihyperglycemic agents at submaximal doses; HbA1c &lt;=10.0% at screening, and 7.010.0% at prerandomisation visit. type 1 diabetes; currently or previously treated with insulin, a thiazolidinedione, or a dual Peroxisome Proliferator Activated Receptor (PPAR) agonist; clinically significant cardiovascular disease; Congestive Heart Failure (CHF) New York Heart Association (NYHA) 34.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>